Construction Spending Rises in June

1 Mins read

Construction spending in the U.S. witnessed a modest increase in June, with both companies and the government initiating more projects across the country.

According to a report by the Commerce Department on Tuesday, spending on construction projects rose by 0.5% in June, reaching $1.94 trillion. However, this figure fell short of the expectations set by economists on Wall Street, who were forecasting a 0.9% rise in construction spending for June.

Construction spending is a key indicator of both government and private sector investment in various projects, including housing and infrastructure. Greater spending in construction generally signals a higher level of economic activity.

The government revised construction spending data for May, increasing it to 1.1% from the initial estimate of a 0.9% rise.

Over the past year, construction spending has shown a steady uptick of 3.5%.

In terms of residential real estate, private residential construction saw a 0.5% increase in June compared to the previous month. Single-family construction experienced significant growth of 2.1% in June, while multifamily construction rose by 1.5%.

Meanwhile, spending on public residential construction edged up by 0.3%. However, the U.S. reduced investment in public residential construction by 0.2%.

The performance of U.S. stocks varied in early trading on Tuesday, with the DJIA (+0.17%) and SPX (-0.28%) showing mixed results. Additionally, the yield on the 10-year Treasury note (TMUBMUSD10Y, 4.046%) crossed the 4% mark.

Related posts

Your Social Security Checks are Safe

2 Mins read
Don’t worry, the impending federal government shutdown will not put your monthly Social Security checks in jeopardy. This is certainly a relief…

European Stocks Experience Decrease

1 Mins read
The European stock market saw a decline on Friday, with the Stoxx Europe 600 index finishing down 0.31% at 453.26. Individual Index…

Positive Results for Cancer-Drug Combination in Bladder Cancer Study

1 Mins read
A recent Phase 3 study conducted by Merck & Co., Seagen, and Astellas Pharma has achieved its primary goals in certain patients…

Leave a Reply

Your email address will not be published. Required fields are marked *